Bleeding Events Higher With Antiplatelet Nonadherence

In patients who had undergone stent implantation, nonadherence to dual-antiplatelet therapy was associated with an increase in ischemic and bleeding events, according to early results from the 5,033-patient PARIS registry.

"There was a sixfold increase in odds for definite or probable stent thrombosis associated with nonadherence compared to adherence to DAPT at 30 days," Dr. Roxana Mehran of Mount Sinai School of Medicine, New York, and coprincipal investigator of the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients: An Observational Single Arm Study) reported at Transcatheter Cardiovascular Therapeutics 2011.

The incidence of nonadherence to dual-antiplatelet therapy at the 30-day follow-up was 2.0%. Among the nonadherent subjects, 69% had disruption of therapy, 19% had interruption, and 12% had discontinuation of therapy, Dr. Mehran said.

The PARIS trial is sponsored by Mount Sinai School of Medicine with grant support from Sanofi-aventis and Bristol-Myers Squibb. Dr. Mehran reported no other financial support from the companies except the research grant.

Note: Based on data for 5,033 patients who received bare-metal or drug-eluting stents.

Source: Dr. Mehran

In patients who had undergone stent implantation, nonadherence to dual-antiplatelet therapy was associated with an increase in ischemic and bleeding events, according to early results from the 5,033-patient PARIS registry.

"There was a sixfold increase in odds for definite or probable stent thrombosis associated with nonadherence compared to adherence to DAPT at 30 days," Dr. Roxana Mehran of Mount Sinai School of Medicine, New York, and coprincipal investigator of the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients: An Observational Single Arm Study) reported at Transcatheter Cardiovascular Therapeutics 2011.

The incidence of nonadherence to dual-antiplatelet therapy at the 30-day follow-up was 2.0%. Among the nonadherent subjects, 69% had disruption of therapy, 19% had interruption, and 12% had discontinuation of therapy, Dr. Mehran said.

The PARIS trial is sponsored by Mount Sinai School of Medicine with grant support from Sanofi-aventis and Bristol-Myers Squibb. Dr. Mehran reported no other financial support from the companies except the research grant.

Note: Based on data for 5,033 patients who received bare-metal or drug-eluting stents.

Source: Dr. Mehran

In patients who had undergone stent implantation, nonadherence to dual-antiplatelet therapy was associated with an increase in ischemic and bleeding events, according to early results from the 5,033-patient PARIS registry.

"There was a sixfold increase in odds for definite or probable stent thrombosis associated with nonadherence compared to adherence to DAPT at 30 days," Dr. Roxana Mehran of Mount Sinai School of Medicine, New York, and coprincipal investigator of the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients: An Observational Single Arm Study) reported at Transcatheter Cardiovascular Therapeutics 2011.

The incidence of nonadherence to dual-antiplatelet therapy at the 30-day follow-up was 2.0%. Among the nonadherent subjects, 69% had disruption of therapy, 19% had interruption, and 12% had discontinuation of therapy, Dr. Mehran said.

The PARIS trial is sponsored by Mount Sinai School of Medicine with grant support from Sanofi-aventis and Bristol-Myers Squibb. Dr. Mehran reported no other financial support from the companies except the research grant.

Note: Based on data for 5,033 patients who received bare-metal or drug-eluting stents.

Source: Dr. Mehran